Matches in SemOpenAlex for { <https://semopenalex.org/work/W4288080701> ?p ?o ?g. }
- W4288080701 endingPage "767" @default.
- W4288080701 startingPage "756" @default.
- W4288080701 abstract "Alzheimer's disease (AD) is the most common degenerative neurological disorder with limited therapeutic options. Therefore, it is particularly important to explore the potential biomarkers implicated in the occurrence and progression of AD prior to clinical testing.We selected 119 unique blood metabolites from 3 metabolome genome-wide association studies (GWASs) with 147,827 European participants. Summary data about AD were obtained from a GWAS meta-analysis with 63,926 European individuals from the International Genomics of Alzheimer's Project. MR analyses were performed to assess the associations of blood metabolites with AD, and a phenome-wide MR analysis was further applied to ascertain the potential on-target side effects of metabolite interventions.Four metabolites were identified as causal mediators for AD, including epiandrosterone sulfate (odds ratio [OR] per SD increase: 0.60; 95% confidence interval [CI]: 0.51-0.71; p = 6.14 × 10-9 ), 5alpha-androstan-3beta-17beta-diol disulfate (OR per SD increase: 0.69; 95% CI: 0.57-0.84; p = 1.98 × 10-4 ), sphingomyelin (OR per SD increase: 2.53; 95% CI: 1.78-3.59; p = 2.10 × 10-7 ), and glutamine (OR per SD increase: 0.83; 95% CI: 0.77-0.89; p = 2.09 × 10-6 ). Phenome-wide MR analysis showed that epiandrosterone sulfate, 5alpha-androstan-3beta-17beta-diol disulfate and sphingomyelin mediated the risk of multiple diseases, and glutamine had beneficial effects on the risk of 4 diseases.Genetically predicted increased epiandrosterone sulfate, 5alpha-androstan-3beta-17beta-diol disulfate, and glutamine might be associated with a decreased risk of AD, while sphingomyelin was associated with an increased risk. Side-effect profiles were characterized to help inform drug target prioritization, and glutamine might be a promising target for the prevention and treatment of AD with no predicted detrimental side effects. ANN NEUROL 2022;92:756-767." @default.
- W4288080701 created "2022-07-28" @default.
- W4288080701 creator A5016141704 @default.
- W4288080701 creator A5024181264 @default.
- W4288080701 creator A5035532030 @default.
- W4288080701 creator A5036235097 @default.
- W4288080701 creator A5059533675 @default.
- W4288080701 creator A5067704857 @default.
- W4288080701 creator A5068947466 @default.
- W4288080701 creator A5079594267 @default.
- W4288080701 creator A5085253928 @default.
- W4288080701 creator A5085329982 @default.
- W4288080701 date "2022-08-15" @default.
- W4288080701 modified "2023-10-18" @default.
- W4288080701 title "Association between Human Blood Metabolome and the Risk of Alzheimer's Disease" @default.
- W4288080701 cites W1703528746 @default.
- W4288080701 cites W1840233714 @default.
- W4288080701 cites W1905058580 @default.
- W4288080701 cites W1972696558 @default.
- W4288080701 cites W1972930653 @default.
- W4288080701 cites W1983540399 @default.
- W4288080701 cites W1989568128 @default.
- W4288080701 cites W2016572613 @default.
- W4288080701 cites W2059865238 @default.
- W4288080701 cites W2065009648 @default.
- W4288080701 cites W2083293065 @default.
- W4288080701 cites W2085392066 @default.
- W4288080701 cites W2115017507 @default.
- W4288080701 cites W2118008714 @default.
- W4288080701 cites W2118822739 @default.
- W4288080701 cites W2126930838 @default.
- W4288080701 cites W2127768736 @default.
- W4288080701 cites W2146249493 @default.
- W4288080701 cites W2156220037 @default.
- W4288080701 cites W2301389244 @default.
- W4288080701 cites W2310542696 @default.
- W4288080701 cites W2503851771 @default.
- W4288080701 cites W2564489970 @default.
- W4288080701 cites W2566039789 @default.
- W4288080701 cites W2580634790 @default.
- W4288080701 cites W2611138580 @default.
- W4288080701 cites W2614566443 @default.
- W4288080701 cites W2623256037 @default.
- W4288080701 cites W2784429314 @default.
- W4288080701 cites W2787612390 @default.
- W4288080701 cites W2799504484 @default.
- W4288080701 cites W2805983714 @default.
- W4288080701 cites W2818417770 @default.
- W4288080701 cites W2897213700 @default.
- W4288080701 cites W2916749909 @default.
- W4288080701 cites W2950099124 @default.
- W4288080701 cites W2950591584 @default.
- W4288080701 cites W2981424908 @default.
- W4288080701 cites W2998178149 @default.
- W4288080701 cites W3005380134 @default.
- W4288080701 cites W3086939852 @default.
- W4288080701 cites W3115500001 @default.
- W4288080701 cites W3203925011 @default.
- W4288080701 cites W3210570897 @default.
- W4288080701 cites W4211214238 @default.
- W4288080701 cites W4211238543 @default.
- W4288080701 cites W4255815262 @default.
- W4288080701 doi "https://doi.org/10.1002/ana.26464" @default.
- W4288080701 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35899678" @default.
- W4288080701 hasPublicationYear "2022" @default.
- W4288080701 type Work @default.
- W4288080701 citedByCount "5" @default.
- W4288080701 countsByYear W42880807012022 @default.
- W4288080701 countsByYear W42880807012023 @default.
- W4288080701 crossrefType "journal-article" @default.
- W4288080701 hasAuthorship W4288080701A5016141704 @default.
- W4288080701 hasAuthorship W4288080701A5024181264 @default.
- W4288080701 hasAuthorship W4288080701A5035532030 @default.
- W4288080701 hasAuthorship W4288080701A5036235097 @default.
- W4288080701 hasAuthorship W4288080701A5059533675 @default.
- W4288080701 hasAuthorship W4288080701A5067704857 @default.
- W4288080701 hasAuthorship W4288080701A5068947466 @default.
- W4288080701 hasAuthorship W4288080701A5079594267 @default.
- W4288080701 hasAuthorship W4288080701A5085253928 @default.
- W4288080701 hasAuthorship W4288080701A5085329982 @default.
- W4288080701 hasConcept C104317684 @default.
- W4288080701 hasConcept C106208931 @default.
- W4288080701 hasConcept C126322002 @default.
- W4288080701 hasConcept C135763542 @default.
- W4288080701 hasConcept C135870905 @default.
- W4288080701 hasConcept C153209595 @default.
- W4288080701 hasConcept C156957248 @default.
- W4288080701 hasConcept C2777477808 @default.
- W4288080701 hasConcept C2779134260 @default.
- W4288080701 hasConcept C2779349466 @default.
- W4288080701 hasConcept C2779483572 @default.
- W4288080701 hasConcept C42407357 @default.
- W4288080701 hasConcept C44249647 @default.
- W4288080701 hasConcept C515207424 @default.
- W4288080701 hasConcept C54355233 @default.
- W4288080701 hasConcept C71924100 @default.
- W4288080701 hasConcept C86803240 @default.
- W4288080701 hasConceptScore W4288080701C104317684 @default.